Ro Body Program Review: How Does It Compare for GLP-1 Access?
An in-depth review of Ro's Body program for GLP-1 weight loss medications. We examine pricing, medication options, provider experience, and how Ro compares to Trimi for patients seeking affordable semaglutide or tirzepatide.
More on GLP-1 Provider Comparisons
What Is the Ro Body Program?
Ro, originally launched as Roman in 2017 with a focus on men's health conditions like erectile dysfunction and hair loss, has grown into one of the larger direct-to-consumer telehealth platforms in the United States. The company rebranded to Ro as it expanded beyond men's health into a comprehensive platform covering dermatology, mental health, fertility, and notably, weight management through its Ro Body program.
The Ro Body program is the company's weight loss vertical, designed to connect patients with licensed healthcare providers who can prescribe GLP-1 medications for weight management. The program follows a familiar telehealth model: patients complete an online health assessment, a provider reviews their information and medical history, and if appropriate, a prescription is issued and medication is shipped to the patient's door.
What distinguishes Ro's approach in the telehealth weight loss space is its historical lean toward brand-name medications. While many newer GLP-1 telehealth platforms have built their businesses primarily around compounded formulations, Ro has at various points emphasized pathways to brand-name GLP-1 drugs like Ozempic and Wegovy. This brand-name orientation has implications for pricing, insurance involvement, and the patient's medication experience. However, Ro has also adapted to market conditions and now offers compounded options as well, making the current landscape more nuanced than a simple brand-name versus compounded distinction.
Understanding how Ro's Body program works in practice — its strengths, limitations, and how it compares to focused GLP-1 platforms like Trimi — requires examining several key dimensions: pricing, medication sourcing, provider expertise, and the ongoing patient experience throughout what is typically a months-long treatment journey.
Ro Body Pricing: What Patients Actually Pay
Ro Body's pricing structure reflects its dual approach to medication access. The program generally offers subscription-based plans that include provider consultations, ongoing monitoring, and medication. However, the actual cost a patient pays depends significantly on which medication pathway they follow — compounded or brand-name — and whether insurance is involved.
For patients accessing compounded GLP-1 medications through Ro, monthly costs have generally started from approximately $99 to $249 per month, depending on the specific medication, dosage tier, and plan length. These prices are in the same general range as many telehealth competitors, though they tend to sit toward the higher end of the compounded GLP-1 market. Ro's pricing may reflect its larger organizational overhead — as a broad telehealth company with multiple verticals, product lines, and a larger corporate structure, its cost basis is different from focused platforms.
For patients pursuing brand-name GLP-1 medications through Ro, the pricing picture changes dramatically. Brand-name Wegovy or Ozempic can cost over $1,000 per month without insurance coverage. Ro has offered services to help patients navigate insurance prior authorization and access manufacturer savings programs, but success depends heavily on the patient's specific insurance plan and coverage policies. This pathway can be valuable for patients with strong insurance coverage for obesity medications, but it introduces complexity and uncertainty that many patients find frustrating.
Trimi's pricing approach is more straightforward by comparison. As a platform built exclusively around affordable GLP-1 access, Trimi offers transparent pricing for compounded semaglutide and tirzepatide without the complexity of navigating insurance pathways or brand-name pricing tiers. For patients whose primary goal is affordable access to effective GLP-1 medication, this simplicity can be a significant advantage in both financial planning and treatment initiation speed.
Cost Comparison Context
GLP-1 telehealth pricing changes frequently as the market evolves. The figures in this article are approximate, based on publicly available information, and should be verified directly with each platform. For a comprehensive analysis of GLP-1 costs across all channels, see our guide on semaglutide pricing.
Medication Options: Brand-Name vs. Compounded
One of Ro's distinguishing features has been its willingness to work with brand-name GLP-1 medications alongside compounded alternatives. This dual-pathway approach provides optionality for patients but also introduces complexity that deserves careful consideration.
Brand-name GLP-1 medications — Ozempic and Wegovy (semaglutide by Novo Nordisk) and Mounjaro and Zepbound (tirzepatide by Eli Lilly) — are FDA-approved products manufactured under strict regulatory oversight. They come in standardized, prefilled injection pens with well-documented dosing protocols. The advantage of brand-name medications is the certainty of standardized manufacturing and the extensive clinical trial data behind the specific formulations. The primary disadvantage is cost: without insurance, these medications typically exceed $1,000 per month and have been subject to widespread supply shortages.
Compounded semaglutide and tirzepatide, which both Ro and Trimi offer, contain the same active pharmaceutical ingredients prepared by licensed compounding pharmacies. These formulations are available under FDA-recognized shortage provisions and are produced by 503A or 503B compounding facilities that must meet regulatory quality standards. Compounded versions typically cost a fraction of brand-name prices, making them the practical choice for most patients paying out of pocket.
Trimi's focus on compounded formulations from vetted 503B pharmacies means that patients receive medications that undergo potency and sterility testing at prices that make long-term GLP-1 therapy financially sustainable. For patients who do not have insurance coverage for brand-name GLP-1 drugs — which is the majority of patients currently seeking these medications — the compounded pathway through a focused platform like Trimi often provides the most accessible and affordable route to effective treatment. Learn more about compounded semaglutide safety standards.
How Prescribing Works on Ro Body
Ro's prescribing process follows the standard telehealth model that has become familiar across the industry. Patients begin by creating an account and completing a detailed health questionnaire that covers medical history, current medications, weight history, BMI, and relevant conditions like type 2 diabetes, cardiovascular disease, or gastrointestinal disorders.
A licensed provider then reviews this information asynchronously — meaning you do not typically have a live video consultation for the initial evaluation. The provider evaluates whether you are a candidate for GLP-1 therapy based on established clinical guidelines (generally requiring a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity). If approved, the provider writes a prescription and the medication is fulfilled through Ro's pharmacy network.
The prescribing experience on Ro benefits from the company's years of telehealth infrastructure development. Their platform is polished and the intake process is well-designed. However, as with many large telehealth platforms, the providers who evaluate weight loss patients also cover other health categories on the platform. The depth of specific GLP-1 expertise can vary from provider to provider.
Trimi's prescribing process is similarly efficient but differs in provider specialization. Because Trimi's board-certified providers work exclusively in the GLP-1 and metabolic health space, the clinical evaluation tends to be more granular around factors specific to GLP-1 prescribing — such as optimal starting dose selection, titration planning, contraindication screening, and anticipatory guidance for managing common side effects like the nausea and GI symptoms that are typical during the first weeks of therapy. For a step-by-step overview of how online GLP-1 prescribing works, see our guide on getting GLP-1 prescribed online.
Pros and Cons of Ro Body for GLP-1 Access
Ro Body: Strengths
Well-established telehealth platform with years of operational experience and a polished user interface
Potential access to brand-name GLP-1 medications for patients with qualifying insurance coverage
Broad health platform that allows management of multiple conditions in one place
Significant venture capital backing and a large provider network across the United States
Insurance navigation support for patients seeking coverage for brand-name medications
Ro Body: Limitations
Pricing tends to be higher than focused GLP-1 platforms, particularly for compounded medications
Brand-name medication pathway introduces insurance complexity and potential denial frustration
Weight loss is one of many verticals — provider GLP-1 specialization may vary
Tirzepatide availability may be more limited compared to dedicated GLP-1 platforms
Some patients report slower turnaround times during periods of high demand
Ro Body vs. Trimi: A Direct Comparison
When comparing Ro Body and Trimi specifically for GLP-1 weight loss access, the key differences come down to focus, affordability, and the trade-offs between breadth and depth of service.
Pricing: Trimi generally offers more competitive pricing for compounded GLP-1 medications. Ro's pricing reflects its larger corporate structure and multi-vertical operations. For patients paying out of pocket — which is most patients seeking compounded GLP-1 medications — the monthly cost difference over a year or more of treatment can add up to hundreds or even thousands of dollars. Understanding the full cost landscape for semaglutide helps put both platforms in context.
Specialization: Trimi's providers focus exclusively on GLP-1 therapy and metabolic health. Ro's providers span multiple health categories. For a medication class that requires careful dose titration, proactive side effect management, and nuanced clinical decision-making, the depth of provider expertise can meaningfully impact treatment outcomes. Patients on Trimi benefit from providers who manage GLP-1 patients all day, every day.
Medication options: Trimi offers both compounded semaglutide and tirzepatide, giving providers and patients flexibility to choose the best molecule for each individual case. Ro's compounded medication options have historically been more semaglutide-focused, though their offerings continue to evolve with the market.
Speed: Trimi's focused operations typically enable faster turnaround from initial assessment to medication delivery. When your entire platform is built around one thing, operational efficiency tends to follow. Ro's broader operations introduce more variables that can affect fulfillment speed.
Where Ro has an edge: For patients who have strong insurance coverage for brand-name GLP-1 medications and want help navigating the prior authorization process, Ro's experience with brand-name pathways can be valuable. Additionally, patients who already use Ro for other health needs may prefer keeping everything on one platform for convenience.
Making Your Decision
Choosing between Ro Body and Trimi ultimately depends on your individual priorities. If you have insurance that covers brand-name GLP-1 medications and want a platform that can help you navigate that pathway, Ro may offer value. If you are paying out of pocket and want the most affordable, specialized, and streamlined path to compounded GLP-1 therapy with board-certified providers who focus exclusively on this treatment area, Trimi is likely the stronger choice.
Both platforms are legitimate telehealth services with licensed providers and real medications. The most important factor is not which platform you choose, but that you start your treatment with proper medical oversight, follow your provider's dosing guidance, and commit to the lifestyle modifications that support long-term weight management success alongside GLP-1 therapy. For a comprehensive overview of how these medications work, explore our complete GLP-1 guide.
Frequently Asked Questions
What is the Ro Body program?
The Ro Body program is a telehealth-based weight management service offered by Ro (formerly Roman). It provides patients access to GLP-1 medications like semaglutide through online consultations with licensed healthcare providers. The program includes an initial health assessment, provider evaluation, ongoing medication management, and access to educational resources. Ro has historically leaned toward brand-name medications but has expanded options over time to include compounded formulations depending on availability and regulatory conditions.
How much does Ro Body cost per month?
Ro Body pricing varies depending on the specific medication prescribed and the subscription plan selected. Programs have generally started from approximately $99 to $249 per month for GLP-1 access, though this can change based on current promotions and medication availability. Some plans may require longer subscription commitments for lower monthly rates. When considering brand-name GLP-1 medications through Ro, patients may need to use insurance or pay significantly higher prices. Always check Ro's current website for the most up-to-date pricing.
Does Ro prescribe brand-name Ozempic or Wegovy?
Ro has historically positioned itself toward brand-name medications and has offered pathways for patients to access brand-name GLP-1 drugs. However, the availability of brand-name Ozempic and Wegovy through Ro depends on current supply conditions, insurance coverage, and patient eligibility. Ro has also expanded into compounded semaglutide options as the compounding market has grown. The specific medications available through Ro may vary at any given time, so patients should confirm current options directly with the platform.
Is Ro a legitimate telehealth company?
Yes, Ro is a well-established telehealth company founded in 2017 (originally as Roman, focused on men's health). The company has raised significant venture capital funding, serves millions of patients, and operates with licensed healthcare providers across multiple states. Ro's providers are licensed physicians and nurse practitioners, and their pharmacy operations partner with licensed facilities. The company has expanded from its original men's health focus into a broad telehealth platform covering weight loss, dermatology, mental health, and other categories.
Can I switch from Ro to Trimi?
Yes, switching from Ro to Trimi is a straightforward process. You would complete Trimi's online health assessment and provide information about your current medication, dosage, and treatment history. A Trimi provider will review your information and can typically continue your treatment at your current dose to ensure continuity. The transition should be timed so that your new Trimi prescription is ready before your current Ro supply runs out, avoiding any gap in treatment that could affect your progress.
Does Ro offer tirzepatide?
Ro's medication offerings have evolved over time. The platform has primarily focused on semaglutide-based programs, and tirzepatide availability through Ro may depend on current regulatory conditions, pharmacy partnerships, and supply. Trimi offers both compounded semaglutide and tirzepatide, providing patients more flexibility to work with their provider in choosing the GLP-1 medication that best fits their clinical profile and treatment response.
What is the difference between Ro Body and Trimi for weight loss?
The primary differences are focus, pricing, and medication options. Ro Body is one weight loss program within a broader telehealth platform that covers many health categories. Trimi is built exclusively around GLP-1 weight loss therapy. Trimi typically offers more affordable compounded GLP-1 options, providers who specialize specifically in metabolic health, and both semaglutide and tirzepatide choices. Ro may offer pathways to brand-name medications for patients with insurance coverage. The best choice depends on whether you prioritize affordability and specialization (Trimi) or a broad-spectrum telehealth relationship with potential brand-name access (Ro).
Sources & References
- Ro Health, Inc. Official Website and Body Program Information. 2026.
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM, 2021;384:989-1002.
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." NEJM, 2022;387:205-216.
- FDA. "Compounding and the FDA: Questions and Answers." U.S. Food and Drug Administration, 2025.
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information. 2024.
- American Telemedicine Association. "Telehealth Practice Guidelines." 2025.
- National Association of Boards of Pharmacy. "Pharmacy Compounding Accreditation." 2025.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Pricing and availability information is approximate and subject to change. This article was prepared by the Trimi Medical Team and naturally reflects our perspective, though we have made every effort to present competitor information fairly and accurately.